Taming Dragons: AI Innovation For Blood Cancer Drug Discovery

CHARM Therapeutics' CEO discusses its DragonFold technology, applying AI to cancer drug hunting, and the benefits of its Nobel Prize-winning roots.

In the rapidly evolving landscape of pharmaceutical innovation, CHARM Therapeutics stands out as a pioneer in leveraging artificial intelligence (AI) to transform drug discovery.

More from C-Suite Speaks

Regenxbio’s Triple Threat: Partnered Programs, DMD Progress And In-House Manufacturing

 
• By 

Regenxbio is riding a wave these days, with all three of its clinical-stage programs set to reach critical milestones this year and recent positive news on its DMD gene therapy, just as Sarepta suffered a setback with a death related to its DMD treatment. In Vivo spoke with CEO Curran Simpson about the company’s plans and strategic decisions.

Taking The Temperature Of UK Biotech 2025

 
• By 

With British Science Week upon us, how are UK life science firms faring, what’s the outlook for the future, and how can the environment be improved to better foster innovation – and make it pay?

Q&A: Rentschler’s CEO On The CDMO’s Pivot Away From Cell And Gene Therapy And More

 
• By 

Rentschler Biopharma CEO Benedikt von Braunmühl tells In Vivo about the CDMO's strategic decision to exit the cell and gene therapy manufacturing space.

20 Voices: What Does 2025 Hold For Biopharma?

 

Twenty executives in the biopharma industry outline their expectations for key trends and developments this year. A selection of commentary from a broad industry survey by Scrip.

More from Innovation

BPGbio: Fusing Patient-Driven Innovation With Causal AI

 
• By 

Biotech BPGbio applies causal AI to generate insights from samples from what the CEO says is one of the world's largest biobanks. With several promising late-stage programs, its platform seems to be yielding fruit.

20 Voices: What Does 2025 Hold For Biopharma?

 

Twenty executives in the biopharma industry outline their expectations for key trends and developments this year. A selection of commentary from a broad industry survey by Scrip.

Biotech Aims For NET Gains By Targeting Neutrophil Extracellular Traps

 
• By 

Neutrophil Extracellular Traps are a double-edged sword in the immune system, capable of both defending against pathogens and driving inflammatory diseases. Their complex role in health and disease is being approached by innovative researchers and biotechs, who are working to harness their power while mitigating their harmful effects.